Stock GILD GILEAD SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Gilead Sciences, Inc.

Equities

GILD

US3755581036

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-29 EDT 		5-day change 1st Jan Change
65.94 USD +0.79% Intraday chart for Gilead Sciences, Inc. -1.51% -18.60%
02:31pm Barclays Adjusts Price Target on Gilead Sciences to $76 From $80 MT
04-26 TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90 MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Barclays Adjusts Price Target on Gilead Sciences to $76 From $80
MT
TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90
MT
Jefferies Adjusts Gilead Sciences' Price Target to $80 From $95
MT
RBC Capital Adjusts Gilead Sciences' Price Target to $74 From $76
MT
Morgan Stanley Adjusts Price Target on Gilead Sciences to $78 From $80
MT
North American Morning Briefing : More Tech -2-
DJ
HSBC Upgrades Gilead Sciences to Hold From Reduce, Price Target is $69
MT
Argus Cuts Price Target on Gilead Sciences to $75 From $85
MT
Cantor Fitzgerald Adjusts Gilead Sciences' Price Target to $75 From $78, Maintains Neutral Rating
MT
BMO Capital Adjusts Price Target on Gilead Sciences to $80 From $89
MT
Leerink Partners Adjusts Gilead Sciences Price Target to $74 From $79
MT
UBS Adjusts Gilead Sciences Price Target to $75 From $81, Maintains Neutral Rating
MT
Goldman Sachs Adjusts Gilead Sciences Price Target to $73 From $76
MT
Morgan Stanley Cuts Price Target on Gilead Sciences to $80 From $83, Keeps Equalweight Rating
MT
Wells Fargo Cuts Price Target on Gilead Sciences to $78 From $84, Keeps Equalweight Rating
MT
Mizuho Securities Cuts Price Target on Gilead Sciences to $90 From $101, Maintains Buy Rating
MT
Truist Securities Downgrades Gilead Sciences to Hold From Buy, Cuts Price Target to $82 From $91
MT
ANALYST RECOMMENDATIONS : Coinbase, Fortinet, Nike, Chipotle, Nvidia...
Our Logo
RBC Trims Price Target on Gilead Sciences to $75 From $76, Keeps Sector Perform Rating
MT
B. Riley Downgrades CymaBay Therapeutics to Neutral From Buy on Heels of Announced Sale to Gilead Sciences, Raises PT to $32.50 From $29
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GILD Stock
  4. News Gilead Sciences, Inc.
  5. Analyst Reco.